ABEONA THERAPEUTICS

Abeona Therapeutics is developing gene therapy-based potential cures for the deadly childhood diseases Sanfilippo (SF) Syndrome Type A and Type B. Its multi-platform expertise across the manufacture, delivery, development, and discovery of the novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery.